Burning Rock Biotech Overview
Valuation check: BNR's P/E ratio is -1.43, below the Healthcare sector average of 25.75.
Get informed when a big investor buys or sells
+ Follow-1.43
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Burning Rock Biotech (BNR) currently reports a P/E ratio of -1.43. That is below the Healthcare sector average of 25.75. Use the charts on this page to explore Burning Rock Biotech's P/E ratio history and peer comparisons.
Burning Rock Biotech's P/E ratio of -1.43 is lower than the Healthcare sector average of 25.75. That is roughly 105.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Burning Rock Biotech's market price to a fundamental measure such as earnings, sales, or book value. At -1.43, BNR can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -1.43, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 25.75. From there, open related valuation or income-statement pages for Burning Rock Biotech, and consider following BNR for alerts when major investors trade the stock.
Burning Rock Biotech is classified in the Healthcare sector. On P/E ratio, it currently shows -1.43 versus a sector average near 25.75. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BNR with unrelated industries.
